Recombinant human EPO is approved for treatment of anemia resulting from chronic kidney failure, chemotherapy and antiviral treatment for Human Immunodeficiency Virus (HIV), and to reduce blood transfusions associated with selected major surgeries. This evidence concerns the gene EPO and anemia.